| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$3 |
Mid-year Market Update
|
28 Feb 2025 9:51AM |
$0.020 |
$0.012 |
fallen by
40%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited focuses on technology innovations improving lives.
- The company has increased sales contracts and reduced operational costs.
- It aims for over 10% growth in international revenues.
- The company is converting its sales pipeline to annual recurring revenues.
- Hydrix has a strong portfolio of innovative products in cardiovascular disease management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$11 |
H1 FY25 Results Presentation
|
28 Feb 2025 9:50AM |
$0.020 |
$0.016 |
fallen by
20%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomo develops innovative rapid tests for point-of-care testing.
- Significant revenue growth of more than 80% in FY24.
- HIV self-testing is projected to grow to US$531m by 2026.
- Atomo is the only registered HIV self-test approved for sale in Australia.
- Active syphilis test development is supported by a $2.44m government grant.
- Atomo's products are registered in more than 30 countries.
- The company has a strong focus on user-centric design and usability.
- Expansion into new markets in Europe and South America is planned.
- Ongoing investment in research and development is aimed at enhancing product offerings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$3 |
Renounceable Rights Issue
|
28 Feb 2025 9:50AM |
$0.009 |
$0.002 |
fallen by
77.78%
|
|
BIT - Price-sensitive ASX Announcement
Full Release
Key Points
- 1 for 1 Renounceable Rights Issue to raise up to $2.7 million
- Priced at 0.3 cents per share
- Discount of 66% to the last price of 0.9 cents
- Shareholders can trade their rights starting from 5 March 2025
- Directors intend to participate for their full entitlements
- Funds to support antiviral programs including BIT225
- Conduct a small animal study of Hepatitis B virus compound
- Maintain existing patents and file new ones
- Rights issue partially underwritten for $750,000 by Mahe Capital
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Motorcycle Holdings Limited (MTO) ORDINARY FULLY PAID |
Consumer Discretionary |
$182 |
Appendix 3Z - Martin Ward
|
28 Feb 2025 9:49AM |
$1.980 |
$2.460 |
risen by
24.24%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$3 |
Trading Update and Growth Outlook
|
28 Feb 2025 9:49AM |
$0.020 |
$0.012 |
fallen by
40%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix recorded consecutive profitable quarters with improved margins and lower operating costs.
- $7.4 million in contract sales orders, a 37% improvement from the previous comparable period.
- Potential future project revenues of $40 million from 15 active clients.
- Cash operating loss significantly improved to $0.39 million from $2.09 million in the prior year.
- Hydrix Medical is expanding sales opportunities in the cardiac and medtech sectors.
- Gyder Surgical received FDA clearance, triggering a $0.36 million valuation increase for Hydrix Ventures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$578 |
Section 708A(5)(e) Notice
|
28 Feb 2025 9:48AM |
$0.455 |
$0.295 |
fallen by
35.16%
|
|
| First Graphene Limited (FGR) ORDINARY FULLY PAID |
Materials |
$19 |
Update - Proposed issue of securities - FGR
|
28 Feb 2025 9:48AM |
$0.041 |
$0.026 |
fallen by
36.59%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,379 |
Challenger neutralises Dividend Reinvestment Plan
|
28 Feb 2025 9:48AM |
$5.950 |
$7.780 |
risen by
30.76%
|
|
| Motorcycle Holdings Limited (MTO) ORDINARY FULLY PAID |
Consumer Discretionary |
$182 |
Director Resignation
|
28 Feb 2025 9:48AM |
$1.980 |
$2.460 |
risen by
24.24%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$355 |
Dividend/Distribution - KSL
|
28 Feb 2025 9:48AM |
$1.170 |
$1.230 |
risen by
5.13%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,379 |
Update - Dividend/Distribution - CGF
|
28 Feb 2025 9:47AM |
$5.950 |
$7.780 |
risen by
30.76%
|
|
| Pier 12 Capital Limited (AVC) ORDINARY FULLY PAID |
Financials |
$44 |
AVC Voluntary Delisting from ASX
|
28 Feb 2025 9:47AM |
$0.615 |
$0.500 |
fallen by
18.70%
|
|
AVC - Price-sensitive ASX Announcement
Full Release
Key Points
- AVC submitted a formal request for delisting on 25 February 2025.
- ASX approved the delisting on 27 February 2025.
- Expected delisting date is 8 May 2025.
- Reasons for delisting include small market capitalization and limited trading liquidity.
- Delisting aims to reduce costs associated with ASX listing.
- Shareholders are advised to sell their shares before 6 May 2025.
- An on-market buyback of shares is proposed, pending shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Delorean Corporation Limited (DEL) ORDINARY FULLY PAID |
Utilities |
$35 |
1H FY2025 Investor Update Presentation
|
28 Feb 2025 9:47AM |
$0.125 |
$0.160 |
risen by
28%
|
|
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$16 |
Issue of Converting Notes
|
28 Feb 2025 9:47AM |
$0.030 |
$0.055 |
risen by
83.33%
|
|
HCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Holista Colltech Limited announces the issuance of converting notes.
- Total raising of approximately AUD1,545,100.
- Funds to enhance working capital and repay ASIC obligations.
- Converting notes feature a maturity date of June 30, 2025.
- Conversion price set at AUD 0.0315 per share.
- Investors include Mr. Greg Pilant and Mr. Tee Kian Heng.
- Mr. Pilant will join the board for a nominal fee.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$578 |
Change of Director's Interest Notice - S. Washer
|
28 Feb 2025 9:47AM |
$0.455 |
$0.295 |
fallen by
35.16%
|
|
| Vital Metals Limited (VML) ORDINARY FULLY PAID |
Materials |
$12 |
Vital Expands Tardiff Scoping Study to Include Niobium
|
28 Feb 2025 9:47AM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
VML - Price-sensitive ASX Announcement
Full Release
Key Points
- Vital expands Tardiff Scoping Study to include niobium recovery.
- Niobium hosted in the same geological formations as rare earth minerals.
- Tardiff estimated to contain 636,000 tonnes of NdPr and 578,000 tonnes of Nb2O5.
- Initial metallurgical testwork showed a 15% recovery rate for niobium.
- Additional testwork will take approximately 8 weeks.
- Vital is working with the Canadian Government to establish a rare earths processing hub.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$536 |
Response to ASX Aware Letter
|
28 Feb 2025 9:46AM |
$3.270 |
$2.730 |
fallen by
16.51%
|
|
ACL - Price-sensitive ASX Announcement
Full Release
Key Points
- ACL issued guidance for FY25 revenue of $725M - $752M and underlying EBIT of $65M - $73M.
- ACL reaffirmed its guidance on multiple occasions including on 26 February 2025.
- All sell-side analysts' forecasts were within ACL's guidance range.
- ACL believes the release of its half-year reports will not materially affect its securities' price.
- ACL confirmed compliance with Listing Rules and has authorized the response to ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$132 |
Dividend/Distribution - JYC
|
28 Feb 2025 9:46AM |
$4.580 |
$4.480 |
fallen by
2.18%
|
|
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$5,380 |
SEC Form 10-K
|
28 Feb 2025 9:46AM |
$21.740 |
$32.070 |
risen by
47.52%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$276 |
Lakeview High-Grade Intercepts Grow Mineralisation
|
28 Feb 2025 9:45AM |
$0.255 |
$0.440 |
risen by
72.55%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Lakeview Prospect's mineralization extended to 400m strike length.
- Best gold intercepts include 19m @ 18.1 g/t Au and 11m @ 24.8 g/t Au.
- Lakeview is located 97km north of Kalgoorlie WA.
- Ongoing drilling at Lakeview and Mulwarrie.
- Lakeview gold mineralization associated with major fault and ultramafic rocks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY25 Results Announcement
|
28 Feb 2025 9:45AM |
$0.135 |
$0.100 |
fallen by
25.93%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023.
- Revenue for 1H FY25 reached A$102,000, a 167% increase from the prior corresponding period.
- Global Expansion: New distribution agreements secured with Accession Medical Supplies and Union MediScience B.S.C.
- Clinical Advancements: The NervAlign® Nerve Guide Matrix showed positive animal study results.
- Successful IPO: Raised $7 million and listed on the ASX on 26 November 2024.
- Surgeon Feedback: Positive reception highlights the NervAlign® Nerve Cuff’s benefits.
- Strong Cash Position: Maintained a cash balance of $6.4 million as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$3 |
Appendix 4D and Half Yearly Report
|
28 Feb 2025 9:45AM |
$0.020 |
$0.012 |
fallen by
40%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited generated revenues of $5,597,012 for the half-year ending December 31, 2024.
- The company reported a loss of $635,660, showing improvement from the previous year's larger loss.
- Operating costs decreased significantly due to cost reduction initiatives.
- Hydrix Services reported its strongest calendar year of sales in the last 5 years.
- The company has a cash position of $1,117,925 as of December 31, 2024.
- 61% of revenue came from international clients.
- The company is focused on driving cash operating profit through sales conversions and higher margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY25 Appendix 4D and Half Year Report
|
28 Feb 2025 9:44AM |
$0.135 |
$0.100 |
fallen by
25.93%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- ReNerve Limited reported a comprehensive loss of $1,843,656 for the half-year ending 31 December 2024.
- The loss increased by 29.8% compared to the previous year.
- The company raised $7 million through an IPO, and shares were listed on the ASX on 26 November 2024.
- US sales increased by around 100% compared to the previous year.
- Partnerships were formed with Accession Medical Supplies in Hong Kong and Mediscience B.S.C. in Bahrain to expand market reach.
- ReNerve is developing the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix with positive clinical outcomes.
- No dividends were declared during the reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$578 |
Notification of cessation of securities - BOT
|
28 Feb 2025 9:44AM |
$0.455 |
$0.295 |
fallen by
35.16%
|
|
| Blackwall Limited (BWF) ORDINARY FULLY PAID |
Financials |
$63 |
Additional Dividend/Distribution - BWF
|
28 Feb 2025 9:44AM |
$0.410 |
$0.375 |
fallen by
8.54%
|
|
BWF - Price-sensitive ASX Announcement
Full Release
Key Points
- New announcement by Blackwall Limited regarding dividend distribution
- Total dividend distribution amount per security is AUD 0.025
- The dividend is fully franked
- Payment date is set for 08/04/2025
- Record date is 11/03/2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
